Citalopram and fluoxetine are both selective serotonin reuptake inhibitors prescribed for depression and anxiety, but they differ in ways that matter for everyday life. Fluoxetine lingers in your body far longer, interacts more aggressively with other medications, and has the strongest regulatory backing for use in children. Citalopram, on the other hand, carries a specific heart-rhythm warning that fluoxetine does not. Choosing between them often comes down to your other medications, your medical history, and which side-effect trade-offs you can tolerate.
How the Two Drugs Work Differently
Both citalopram and fluoxetine block the serotonin transporter, the protein that vacuums serotonin back into nerve cells after it has been released. That shared mechanism is what makes them both SSRIs. But beyond that core action, they are not identical. Citalopram is among the most selective SSRIs, meaning it mostly just blocks serotonin reuptake and does relatively little else at the receptor level. Fluoxetine, by contrast, also binds to the 5-HT2C serotonin receptor with moderate affinity, something citalopram does to a much lesser degree.
In binding studies, fluoxetine showed a substantially higher affinity for the 5-HT2C receptor compared with citalopram.1PubMed. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor That receptor is involved in mood, appetite, and arousal, and blocking it may partly explain why fluoxetine feels more “activating” to some people. Patients who find fluoxetine energizing or even jittery sometimes do better on citalopram, which tends to have a calmer profile. Neither drug is universally better; the differences in receptor activity just mean they can feel different in practice.
Half-Life and What It Means for Missed Doses
This is one of the biggest practical differences between the two drugs, and it affects everything from what happens when you forget a dose to how long you need to wait before starting a new medication. Fluoxetine has an unusually long half-life for an antidepressant. The parent drug sticks around for two to four days, and its active metabolite, norfluoxetine, can linger for one to two weeks.2PubMed. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability Citalopram’s half-life is roughly one day, which is typical for most SSRIs.
In daily life, fluoxetine’s long half-life acts as a built-in buffer. If you miss a dose, blood levels barely dip, and you are less likely to feel withdrawal-like symptoms. Citalopram, with its shorter half-life, is less forgiving of missed doses. People who skip a day or two of citalopram sometimes notice dizziness, irritability, or “brain zaps” that rarely happen with fluoxetine.
The flip side is that fluoxetine’s long tail makes it slower to clear your system. If you need to switch to a different antidepressant, especially one like a monoamine oxidase inhibitor, prescribers typically require a washout period of at least five weeks after stopping fluoxetine. With citalopram, that window is much shorter, usually around two weeks. So fluoxetine’s forgiveness when you miss a pill comes at the cost of less flexibility when it is time to change course.
Drug Interactions
If you take other medications, this is where the two drugs diverge most sharply. Fluoxetine is a potent inhibitor of the liver enzyme CYP2D6, which is responsible for breaking down a wide range of drugs, including certain painkillers, beta-blockers, antipsychotics, and even the breast-cancer drug tamoxifen.3PubMed. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update When fluoxetine slows down CYP2D6, those other drugs can build up to higher-than-expected levels in your blood, raising the risk of side effects or toxicity.
Citalopram, in contrast, is a weak inhibitor of CYP enzymes across the board. In dose-escalation studies, citalopram caused only modest increases in the markers used to measure CYP2D6 activity, while fluoxetine produced much more pronounced inhibition. Fluoxetine also significantly inhibited CYP2C19, whereas citalopram did not.4PubMed. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine For people on multiple medications, citalopram’s cleaner interaction profile is a genuine advantage. It is one of the reasons clinicians gravitate toward citalopram or its close relative escitalopram for older adults on complicated medication regimens.
Heart Rhythm and QT Prolongation
Citalopram’s main safety concern involves the heart. In 2011, the FDA issued an advisory warning that citalopram can prolong the QT interval on an electrocardiogram in a dose-dependent way, and it capped the recommended maximum dose at 40 mg per day for most adults (20 mg for those over 60 or with liver impairment). Among the SSRIs, citalopram and escitalopram prolong the QT interval to the greatest extent.5PubMed Central. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis
Fluoxetine does not carry the same degree of QT concern. A review of the literature found that fluoxetine, fluvoxamine, and sertraline at standard doses showed a lack of clinically significant QT prolongation in most studies, and paroxetine appeared to carry the lowest risk of all.6Annals of Pharmacotherapy. A Comparison of the Risk of QT Prolongation Among SSRIs For patients who already have cardiac risk factors, who take other QT-prolonging medications, or who have electrolyte imbalances, this difference can steer the choice away from citalopram and toward fluoxetine or another SSRI.
In a large cohort of hemodialysis patients, those receiving SSRIs with higher QT-prolongation potential (citalopram and escitalopram) had a higher risk of sudden cardiac death compared with those on lower-risk SSRIs like fluoxetine and sertraline.7PubMed Central. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis That is an extreme population with already vulnerable hearts, but the signal reinforces why the dose ceiling on citalopram exists and why cardiac history matters when choosing between these two.
Sexual Side Effects
Sexual dysfunction is one of the most common reasons people stop taking an SSRI, and it occurs with both citalopram and fluoxetine. But there is some evidence that the two drugs are not equivalent here. In a double-blind, placebo-controlled trial in healthy men, both drugs delayed ejaculation compared with placebo. However, citalopram produced a statistically significant delay while fluoxetine’s delay did not quite reach significance. Citalopram also led to significantly lower scores on a standardized sexual-function questionnaire across most domains, while fluoxetine’s scores were lower but not statistically different from placebo. Neither drug affected sexual desire in that study.8PubMed. The effects of citalopram and fluoxetine on sexual behavior in healthy men: evidence of delayed ejaculation and unaffected sexual desire. A randomized, placebo-controlled, double-blind, double-dummy, parallel group study
A single trial in healthy volunteers is not the final word, and real-world experience varies widely. But it is worth noting that citalopram showed a slightly heavier sexual side-effect burden in the one controlled comparison available. If sexual function is a high priority for you, this is a conversation worth having with your prescriber, ideally before starting treatment rather than after problems develop.
Anxiety and Panic Disorder
Both drugs are used off-label (or on-label depending on the country) for anxiety conditions, and both work. In a study comparing them head-to-head in panic disorder, fluoxetine and citalopram showed similar overall efficacy, with high rates of sustained remission during long-term follow-up. Fluoxetine appeared to act faster, reducing generalized anxiety, spontaneous panic attacks, and anticipatory anxiety sooner than citalopram did. There was also a dosing difference: fluoxetine showed effectiveness at 10 mg per day, while citalopram needed about 30 mg per day to reach the same point.9Human Psychopharmacology: Clinical and Experimental. Short-term and long-term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram
That faster onset with fluoxetine may relate to its extra receptor activity beyond pure serotonin reuptake blockade. For someone in acute distress from panic attacks, a few weeks’ head start on symptom relief can feel enormous. On the other hand, citalopram catches up with continued use, so the long-term picture looks similar.
Use in Children and Adolescents
Fluoxetine has a significant edge in the pediatric space. It is the only SSRI with FDA approval for depression in children aged eight and older, and the evidence behind that approval is more robust than for any other antidepressant in this age group. A network meta-analysis of antidepressant trials in adolescent depression found that fluoxetine was significantly better than placebo on a widely used depression rating scale.10PubMed Central. Comparative efficacy of antidepressant medication for adolescent depression: a network meta-analysis and systematic review
Citalopram has some pediatric data, but the picture is muddier. Of two randomized controlled trials, only one showed citalopram beating placebo on its primary measure. One trial also reported numerically higher suicide-related events with citalopram compared with placebo, though the difference did not reach statistical significance. As a result, current guidance generally considers citalopram (and escitalopram) a second-line option for adolescent depression, behind fluoxetine.11PubMed Central. A review of escitalopram and citalopram in child and adolescent depression
This does not mean citalopram is never used in younger patients. If a teenager does not respond to fluoxetine or cannot tolerate it, prescribers may try citalopram or escitalopram. But fluoxetine’s stronger trial record and its longer half-life, which can be protective in an age group where adherence is inconsistent, make it the default first choice.
Pregnancy Considerations
No SSRI is entirely free of concern during pregnancy, but the data suggest the risks for both citalopram and fluoxetine are in a similar ballpark: small in absolute terms, but not zero. A large meta-analysis pooling cohort studies covering more than nine million births found that first-trimester use of either fluoxetine or citalopram was associated with a roughly 17 to 20 percent relative increase in the risk of major congenital anomalies and a 24 to 30 percent increase in the risk of congenital heart defects.12PubMed Central. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births In absolute numbers, those relative increases translate to a very small number of additional affected pregnancies.
A separate meta-analysis focused specifically on fluoxetine found a slightly elevated risk of cardiovascular malformations, particularly septal defects, with first-trimester exposure.13PubMed Central. Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies For citalopram, one case-control study noted an association with diaphragmatic hernia, though the confidence interval was wide and the absolute risk was very low.14JAMA Psychiatry. Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects
A critical caveat: when researchers controlled for the underlying psychiatric condition itself, many of the associations between SSRIs and birth defects weakened or disappeared. Untreated depression during pregnancy carries its own risks, including preterm birth, low birth weight, and complications from self-harm. The decision to continue or stop an SSRI during pregnancy is always a risk-versus-risk calculation, not a risk-versus-safety calculation, and it should be made with a clinician who knows your history.
Bulimia Nervosa and Eating Disorders
Fluoxetine has a specific FDA approval for bulimia nervosa, typically at the higher dose of 60 mg per day, making it one of the few medications formally indicated for that condition. Citalopram has been studied for bulimia as well. In a head-to-head trial, both drugs improved eating-related symptoms, anger, and overall clinical impression. The two drugs showed different strengths, however: fluoxetine was more effective at reducing internalized anger, while citalopram was better at reducing depressive symptoms in patients with bulimia.15PubMed. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial
In practice, though, citalopram’s dose ceiling from the QT-prolongation warning has limited its usefulness for bulimia. Higher doses tend to be needed for eating disorders, and the maximum recommended dose of citalopram may not be enough to reach full therapeutic effect for many patients.16The Psychopharmacology Institute. Pharmacotherapy of Eating Disorders: An Update For that reason, fluoxetine remains the go-to SSRI for bulimia in most clinical settings.
Adherence and Persistence
Sticking with an antidepressant long enough for it to work is half the battle. A retrospective study of veterans with major depressive disorder found that fluoxetine had significantly higher adherence and lower discontinuation rates compared with citalopram.17International Clinical Psychopharmacology. Comparing adherence and persistence of common selective serotonin reuptake inhibitors in veterans with major depressive disorder: a retrospective analysis of Veterans Affairs healthcare data Fluoxetine’s long half-life likely contributes: missed doses do not cause immediate symptom rebound, so intermittent lapses are less punishing, and patients may be less likely to give up after a rough few days.
This does not mean fluoxetine is inherently easier to take. Some people find its activating quality or its lengthy washout period to be drawbacks. And adherence data from a veteran population may not generalize perfectly to all patients. But the pattern makes intuitive sense, and it is one more factor to weigh if you know your medication-taking habits are imperfect.
The Escitalopram Connection
You cannot compare citalopram and fluoxetine without mentioning that citalopram has a refined sibling. Citalopram is a racemic mixture, meaning it contains equal parts of two mirror-image molecules, the S-enantiomer and the R-enantiomer. The S-enantiomer was isolated and marketed as escitalopram (Lexapro), and it is responsible for essentially all of citalopram’s antidepressant activity. The R-enantiomer contributes little therapeutically and may even slightly interfere with the S-enantiomer’s binding.18PubMed. Enantiomers’ potential in psychopharmacology–a critical analysis with special emphasis on the antidepressant escitalopram
In practical terms, escitalopram at 10 mg delivers roughly the same serotonin-blocking punch as citalopram at 20 mg, but with a somewhat cleaner side-effect profile in some studies. Escitalopram also showed strong results in the adolescent network meta-analysis mentioned earlier, performing well on global functioning and clinical improvement scores.19PubMed Central. Comparative efficacy of antidepressant medication for adolescent depression: a network meta-analysis and systematic review If you are already considering citalopram, it is worth asking your prescriber whether escitalopram might be a better-tolerated alternative, especially now that generic escitalopram is widely available and no longer carries the price premium it once did.
When Each Drug Tends to Be the Better Fit
Neither citalopram nor fluoxetine is categorically superior. The choice depends on your individual situation, and a few patterns emerge from the evidence. Fluoxetine tends to be preferred when you need strong pediatric data, when you are prone to missing doses, when you want the FDA-approved option for bulimia, or when cardiac risk factors make QT prolongation a concern. Citalopram tends to be favored when you are taking multiple other medications and need to minimize drug interactions, when you may need to switch antidepressants in the near future and want a shorter washout, or when a calmer, less activating profile suits you better.
Age matters, too. Older adults on several medications often end up on citalopram or escitalopram precisely because of the clean interaction profile, but the QT warning then limits the maximum dose. For some older patients, that cap means they cannot reach the dose they need, at which point fluoxetine or sertraline may work better despite the extra interaction monitoring required. These trade-offs are rarely clean, and they are exactly the kind of thing a pharmacist or prescriber can help you navigate with your full medication list in hand.